SAN DIEGO, Feb. 08, 2017 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will present at the Leerink Partners 6th Annual Global Healthcare Conference in New York City on Wednesday, February 15, 2017 at 10:00 a.m. ET.
A live webcast of the presentation will be available through the investor relations section of the Company's website at www.fatetherapeutics.com. Following the live webcast, an archived replay will be available on the Company's website.
About Fate Therapeutics, Inc.
Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The Company's hematopoietic cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf product candidates derived from engineered induced pluripotent cell lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients undergoing hematopoietic cell transplantation and to promote immune tolerance in patients with autoimmune disease. Its adoptive cell therapy programs are based on the Company's novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact: Christina Tartaglia Stern Investor Relations, Inc. 212.362.1200 [email protected]


Anta Sports Expands Global Footprint With Strategic Puma Stake
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 



